{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-22-016263","form_type":"8-K","ticker":"NXTC","cik":"0001661059","company_name":"NextCure, Inc.","filed_at":"2022-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.611844+00:00","generated_at":"2026-06-22T09:22:16.168369+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"NextCure discontinues NC318 program; Q3 net loss $18.9M, cash runway extended to mid‑2025","bullets":["Discontinued NC318 development after no responses in Phase 2 monotherapy; continuing Yale combo trial.","Cash, cash equivalents and marketable securities at Sept 30, 2022: $169.2M, down from $219.6M at Dec 31, 2021.","Q3 2022 net loss $18.9M vs $17.9M in Q3 2021; R&D expense flat at $13.5M, G&A up to $5.7M.","Cash runway extended by 15 months; now expected to fund operations into mid‑2025.","Advancing NC410 Phase 1b/2 combo trial, NC525 Phase 1 expected Q1 2023, and NC762 expansion."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-22-016263","json":"https://secwatch.observer/filing/0001558370-22-016263.json","markdown":"https://secwatch.observer/filing/0001558370-22-016263.md","text":"https://secwatch.observer/filing/0001558370-22-016263.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1661059/000155837022016263/0001558370-22-016263-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1661059/000155837022016263/nxtc-20221103x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T09:22:16.168369+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9c770f6f512c5ca32c680172007ca18cc8834038","claim":"NextCure, Inc. reported the quarter ended September 30, 2022 results: net income Net loss was $18.9 million for the quarter ended September 30, 2022.","evidence_excerpt":"Net loss was $18.9 million for the quarter ended September 30, 202 2, as compared with a net loss of $17.9 million for the quarter ended September 30, 2021.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1661059/000155837022016263/0001558370-22-016263-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2022"},{"label":"Net income","value":"Net loss was $18.9 million for the quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}